Taltorvic ridaforolimus regulatory update

FDA's Oncologic Drugs Advisory Committee voted 13-1 that Taltorvic ridaforolimus from Merck did not demonstrate a favorable benefit-risk profile as a maintenance therapy for metastatic soft tissue or ...